Magnetic detection of sentinel lymph node in papillary thyroid carcinoma: The MAGIC-PAT study results

• Published in: European journal of surgical oncology Vol. 45; no. 7; pp. 1175 - 1181
• Main Authors: Baena Fustegueras, Juan Antonio, González, Fernando Herrerías, Calderó, Sònia Gatius, de la Fuente Juárez, Ma Cruz, López, Susana Ros, Riu, Ferran Rius, Petit, Núria Mestres, Álvarez, Pablo Muriel, Torelló, Albert Lecube, Matias-Guiu, Xavier, Olsina Kissler, Jorge Juan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-07-2019
• Subjects: Magnetic tracer; Sentinel lymph node biopsy; Superparamagnetic iron oxide (SPIO); Thyroid carcinoma; LN; Magnetic tracer; NSLN; CCD; MRI; SPIO; Superparamagnetic iron oxide (SPIO); FNR; SLNB; ATA; Thyroid carcinoma; SC; DTC; OSNA; rSLNB; SLN; NPV; Sentinel lymph node biopsy; AJCC; ETE; PPV; RAI; mSLNB; PTC
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2019.03.017

Despite the controversy concerning sentinel lymph node biopsy (SLNB) in papillary thyroid carcinoma (PTC), successful detection rates can be achieved by radioguidance and vital dyeing. However, the drawbacks in both techniques are notable. Magnetic-guided SLNB (mSLNB) using superparamagnetic iron oxide (SPIO) nanoparticles is appealing as an alternative procedure.
mSLNB using the Sentimag-Sienna System®, total thyroidectomy and central compartment dissection (CCD) were performed on all PTC patients. Lymph node involvement was assessed by postoperative pathological examination.
From 2014 to 2016, 33 consecutive patients with PTC were enrolled in the study. A total of 20 patients met the eligibility. mSLNB succeeded in 16 patients, with a detection rate of 80%. A median of two SLN per patient were detected. A median of 10.5 non-sentinel lymph nodes (NSLN) from CCD were examined. Among the patients, 56.25% (9/16) had no metastatic nodes, while 12.5% (2/16) had exclusively SLN involvement. No false negative cases were found. The agreement between SLN and NSLN status was 87.5%. The prediction of NSLN involvement by SLN status showed 100% sensitivity, 81.8% specificity, 71.4% PPV and 100% NPV. Subsequently, mSLNB and the final pathological analysis would discriminate 43.75% (7/16) of patients who would certainly benefit from CCD whilst 56.25% of the total would confirm an unnecessary lymphadenectomy and avoid morbidity.
mSLNB showed satisfactory performance in PTC with clinical-negative nodes. We have shown mSLNB to be a good predictor of central compartment status that can improve the staging and management of PTC patients.